2/29/2024 0 Comments Orbis clinical trialJEMPERLI was approved under FDA’s accelerated approval program, which provides earlier patient access to a promising new drug while the company continues to conduct clinical trials to confirm that the drug works well. For most patients (93.3%), the response lasted more than 6 months. In the trial, JEMPERLI 42.3% of patients had a decrease in the size of their tumors (29.6%), or their tumors could no longer be detected (12.7%). The healthcare provider will decide how many treatments are needed. JEMPERLI is usually given every 3 weeks for the first 4 doses, and then beginning 3 weeks later, it is usually given every 6 weeks. JEMPERLI is given into the vein through an intravenous (IV) line. you have received certain types of chemotherapy that did not work or are no longer working.the tumor has returned, or it has spread (advanced cancer), and.the tumor has been shown by a laboratory test to be mismatch repair deficient (dMMR), and.JEMPERLI is a prescription medicine used to treat adult females with uterine cancer (endometrial cancer). Snapshots are limited to the information available at the time of the original approval of the drug and do not provide information on who participated in clinical trials that supported later approvals for additional uses of the drug (if applicable).ĭRUG TRIALS SNAPSHOT SUMMARY: What is the drug for? Refer to the JEMPERLI Prescribing Information for all of the approved conditions of use of this drug (e.g., indication(s), population(s), dosing regimen(s), safety information). Some of the information in this Snapshot is for presentation purposes and does not represent the approved conditions of use of this drug. Always speak to your healthcare provider about the benefits and risks of a drug. The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the drugs.ĭo not rely on Snapshots to make decisions regarding medical care. The “MORE INFO” bar shows more detailed, technical content for each section. The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |